Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jun;6(3):177-184.
doi: 10.1159/000462153. Epub 2017 Mar 9.

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

Masatoshi Kudo
Editorial

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

Masatoshi Kudo. Liver Cancer. 2017 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Treatment strategy for systemic therapy for hepatocellular carcinoma. Identification of the subgroup that easily develops to transarterial chemoembolization (TACE) failure/refractoriness may be important. For that subgroup, systemic therapy with a lenvatinib/sorafenib-regorafenib sequence may be a more adequate treatment strategy than repeating ineffective TACE for improving patient survival/benefit. BSC, best supportive care; OS, overall survival.
Fig. 2
Fig. 2
Heterogeneity and treatment strategy for intermediate-stage hepatocellular carcinoma. Substage B2 (bilobar multiple nodules) may be a candidate for clinical trials of transarterial chemoembolization (TACE) combination therapy with tyrosine kinase inhibitors or immunotherapy. This subgroup may easily become refractory to TACE. CP, Child-Pugh; RFA, radiofrequency ablation; cTACE, conventional subsegmental Lipiodol TACE; DEB, drug-eluting beads; HAIC, hepatic arterial infusion chemotherapy. Modified with permission by Kudo et al. [12].
None
See this image and copyright information in PMC

References

    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. - PubMed
    1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. - PubMed
    1. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–4075. - PubMed
    1. Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–3524. - PubMed
    1. Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–179. - PMC - PubMed

Publication types